SearchDictionaryMobileLogin

Nail psoriasis and biologics.

AbstractBACKGROUND: Since the advent of biologic therapies for psoriasis, reports of efficacy in nail psoriasis have appeared in the literature and at international conferences with increasing frequency. OBJECTIVE: This article aims to review the existing literature on the use of biologics in the treatment of nail psoriasis. METHODS: An extensive literature review was conducted using OVID Medline. Studies examining the efficacy of biologics in the treatment of nail psoriasis were documented. RESULTS: A literature review revealed few clinical trials specifically concentrating on nail psoriasis; however, nails have been assessed in larger clinical trials for cutaneous psoriasis. A large, multicenter, phase III, double-blind, placebo-controlled study of infliximab administered as a brief induction regimen at weeks 0, 2, and 6 followed by a single infusion every 8 weeks revealed statistically significant mean percent improvement in the Nail Psoriasis Severity Index (NAPSI) score over placebo at both week 10 (26.8% vs -7.7%, respectively; p < .001) and week 24 (57.2% vs -4.1%, respectively; p < .001). For other biologics, evidence has thus far been largely anecdotal, appearing as either case studies or extracted secondarily from open-label prospective trials in plaque psoriasis or psoriatic arthritis. CONCLUSION: Infliximab appears to be the most effective treatment for nail psoriasis to date.
AuthorsKristin Noiles, Ronald Vender (Affiliation: Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON. kristin.noiles at medportal.ca)
JournalJournal of cutaneous medicine and surgery (J Cutan Med Surg) 2009 Jan-Feb Vol. 13 Issue 1 Pg. 1-5 ISSN: 1203-4754 [Print] Canada
PMID19298765 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Immunologic Factors
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • efalizumab
  • infliximab
  • TNFR-Fc fusion protein
  • alefacept
Topics
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Humans
  • Immunoglobulin G (administration & dosage, therapeutic use)
  • Immunologic Factors (administration & dosage, therapeutic use)
  • Nail Diseases (drug therapy)
  • Psoriasis (drug therapy)
  • Receptors, Tumor Necrosis Factor (administration & dosage, therapeutic use)
  • Recombinant Fusion Proteins (administration & dosage, therapeutic use)